JNJ生命科学与高端医疗● Live Quotes Active

Johnson & Johnson

No mega hedge funds in our coverage currently report a major 13F position in this stock

Live Price
24h Change
Mega Funds Holding
0/ 33 funds

Coverage: 0.0%

Avg Portfolio Weight
0%

-

Wall St Sentiment
0%Bullish
+0/0/-0
Total Tracked Shares
0shares

Based on SEC 13F filings

SGDC Dual-Core EngineSuper-Growth Dual-Core Radar

🚀JNJ SGDC Quant Rating & Setup

Open SGDC Screener↗
4P Grade
C 级(66分)
RS Rating
55/ 99
Pattern Setup
Base Setup
Pivot Benchmark
$282.02Support: $260.87

📌 Business Moat Summary:Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

ℹ️
13F Hedge Fund Coverage NoticeNone of the 33 tracked mega hedge funds (e.g., Berkshire Hathaway, Bridgewater, Renaissance, Citadel) currently report a major 13F position in JNJ.✦ Note: This stock is actively tracked by the SGDC Super-Growth Quant Engine (4P Grade C, RS Rating 55).

📈8-Quarter Institutional Ownership Evolution

Historical trajectory of institutional holders and allocation weight across the last 8 quarters

Select Quarter:
0% 均仓
0 f2026 Q2
0% 均仓
0 f2026 Q1
0% 均仓
0 f2025 Q4
0% 均仓
0 f2025 Q3
0% 均仓
0 f2025 Q2
0% 均仓
0 f2025 Q1
0% 均仓
0 f2024 Q4
0% 均仓
0 f2024 Q3
2026 Q2|Report Date: 2026-06-30
Holding Funds: 0 家Total Shares: 0Avg Weight: 0%

🏛️Institutional Investors Holding this Stock

Examine each hedge fund holding this ticker, weight, shares, and recent action

Sort by:
Manager / FundFund AUMWeightShares HeldActionAction
No tracked mega hedge funds currently hold this stock.
🎯

Want to see Wall Street's Top 50 Consensus Buys?

Instead of checking individual stocks, get the complete list of high-conviction overlap picks across 33 hedge funds.

Go to Consensus Screener →

⚡Planning to trade JNJ?

Add this symbol to your private journal or dividend tracker to monitor institutional moves.